CYCC News and Press, Cyclacel Pharmaceuticals Inc. From 03/12/21

BERKELEY HEIGHTS, N.J., March 12, 2021 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced the pricing of an underwritten...

Cyclacel Pharmaceuticals (CYCC) trades 10.7% down after hours on planning to offer shares for sale in an underwritten public offering; underwriters granted 30-day option to purchase up to an additional 15% of the shares.Offer size, terms not yet disclosed.Net proceeds to be used for...

Cyclacel Pharmaceuticals (CYCC) announces that it intends to offer shares for sale in an underwritten public offering.Intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares.Cyclacel did not provide further financial details on the offering.The comp...

BERKELEY HEIGHTS, N.J., March 11, 2021 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, announced today that it intends to offer share...

Cyclacel Pharmaceuticals, Inc. (CYCC) Q4 2020 Results Conference Call February 25, 2021 04:30 PM ET Company Participants Jason Assad - Investor Relations Spiro Rombotis - President and Chief Executive Officer Paul McBarron - Executive Vice President, Finance and Chief Operating Officer Dr. Ma...

Cyclacel Pharmaceuticals (CYCC): Q4 GAAP EPS of -$2.74 misses by $2.21.As of December 31, 2020, cash and cash equivalents totaled $33.4 million. Additional proceeds of $4.3 million were received from the exercise of warrants after December 31, 2020. Based on current spending, the proforma cas...

BERKELEY HEIGHTS, N.J., Feb. 25, 2021 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company") a biopharmaceutical company developing innovative medicines based on cancer cell biology, today reported its financial results and business hig...

BERKELEY HEIGHTS, N.J., Feb. 19, 2021 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, will announce fourth quarter and full year 2020 fina...

BERKELEY HEIGHTS, N.J., Feb. 10, 2021 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced that the Company will present at the...

Gainers: Ceragon Networks (CRNT) +67%.ObsEva (OBSV) +60%.Polar Power (POLA) +50%.Charah Solutions (CHRA) +46%.Avinger (AVGR) +45%.DBV Technologies (DBVT) +42%.Novan (NOVN) +42%.Senseonics (SENS) +42%.Atlantic Power (AT) +40%.Driven Brands (DRVN) +31%.Losers: Dogness (DOGZ)...